C5 and paroxysmal nocturnal hemoglobinuria: Currently, a Phase III study (NCT04469465) examining the therapeutic value of ALXN2040 as an add-on therapy to a C5 inhibitor is underway in patients with PNH who develop extravascular hemolysis (98).